BACOP                                                lymphoma(84)
 _________________________________________________________________
  bleomycin....... 4 U/sqm IV on days 1, 5, 8, 12, 15, and 19.
  adriamycin...... 45 mg/sqm IV day 1.
  cytoxan......... 600 mg/sqm IV day 1.
  vincristine..... 1.2 mg/sqm IV on days 1, 8, and 15.
  prednisone...... 40 mg/sqm/day orally over days 1 to 21, then 
                   taper.
  FREQUENCY....... Repeat cycle every 21 days.

  reference...
    Skarin AT.  Rosenthal DS.  Moloney WC.  Frei E 3d. Combination 
    chemotherapy of advanced non-Hodgkin lymphoma with bleomycin, 
    adriamycin, cyclophosphamide, vincristine, and prednisone 
    (BACOP). Blood.  49(5):759-70, 1977 May. 
  abstract...
    Seventy-three patients with advanced non-Hodgkin lymphoma were 
    treated with bleomycin, Adriamycin, cyclophosphamide, 
    vincristine (Oncovin) and prednisone (BACOP), administered 
    intensively during a 7-wk induction course followed by 
    intermittent cycles every 3 wk for a total of 28 wk. The 
    objective response in 44 evaluable nonleukemic patients with 
    diffuse histology was 86%, with 66% achieving a complete 
    remission (CR), varying from 80% for diffuse poorly 
    differentiated lymphocytic (DPDL) to 56% for diffuse 
    histiocytic (DH) lymphoma. In patients with nodular histology 
    89% (8/9) achieved a CR with a projected 75% of patiients in 
    CR at 14 mo. Median follow-up from time of CR for nodular 
    histology was 17 mo. The projected median duration of CR in 
    diffuse histology was 14 mo. with median survival 14 mo. 
    Patients with a partial response survived a median of 7 mo, 
    compared to 3 mo for nonresponders. Of 29 patients with 
    diffuse histology, 17 (59%) have remained disease free for 
    5-34 mo with a median follow-up of 12 mo. Survival beyond 20 
    mo has been projected for 42% of patients with diffuse 
    histology (58% with DPDL and 32% with DH). The central nervous 
    system (CNS) was involved in a total of 11/44 (25%) patients 
    with diffuse histology, including 5 with primary CNS relapse. 
    BACOP resulted in a higher CR rate and longer survival than a 
    previous three-drug program (COP), especially in patients with 
    diffuse histology.